Home » Stocks » INVA

Innoviva, Inc. (INVA)

Stock Price: $11.73 USD 0.21 (1.82%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 1.19B
Revenue (ttm) 343.63M
Net Income (ttm) 253.09M
Shares Out 101.37M
EPS (ttm) 2.27
PE Ratio 5.17
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $11.73
Previous Close $11.52
Change ($) 0.21
Change (%) 1.82%
Day's Open 11.47
Day's Range 11.45 - 11.79
Day's Volume 847,979
52-Week Range 9.21 - 15.62

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ:INVA) (“Innoviva” and “the Company”) today reported financial results for the first quarter ended March 31, 2021. Gross royalty revenues of $8...

1 week ago - Business Wire

Other stocks mentioned: BIO, SAGE
1 month ago - GuruFocus

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders took advantage of initial public offerings in the past week.

Other stocks mentioned: CPNG, KDP, BHVN, GOCO, JOAN, MBIN, PFSI ...
1 month ago - Benzinga

The Dow slipped 0.1%, the S&P 500 rose 0.1%, and the Nasdaq climbed 0.6%. In the meantime, Q.ai's Artificial Intelligence has brought out today's top buys.

Other stocks mentioned: AAWW, CBT, GOLF, KWR
1 month ago - Forbes

Innoviva (INVA) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

2 months ago - Zacks Investment Research

Shares of Innoviva (NASDAQ:INVA) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 14.29% over the past year to $0.48, which beat th...

3 months ago - Benzinga

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter ended December 31, 2020. Gross royalty revenues of $93.9 million ...

3 months ago - Business Wire

Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter.

3 months ago - Zacks Investment Research

In the latest trading session, Innoviva (INVA) closed at $12.51, marking a +1.71% move from the previous day.

3 months ago - Zacks Investment Research

Top Ranked Value Stocks to Buy for January 5th

Other stocks mentioned: CUBI, PAGP, SWBI
4 months ago - Zacks Investment Research

Top Ranked Value Stocks to Buy for January 4th

Other stocks mentioned: DAC, MIK, ODP
4 months ago - Zacks Investment Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

4 months ago - Zacks Investment Research

Top Ranked Value Stocks to Buy for December 29th

Other stocks mentioned: MIK, ODP
4 months ago - Zacks Investment Research

Top Ranked Value Stocks to Buy for December 28th

Other stocks mentioned: AMRK
4 months ago - Zacks Investment Research

To combat market volatility, create a portfolio of low-beta stocks.

Other stocks mentioned: CWT, EGOV, OMI, VSTO
4 months ago - Zacks Investment Research

Top Ranked Value Stocks to Buy for December 24th

Other stocks mentioned: CLW, MIK
4 months ago - Zacks Investment Research

We believe that Innoviva stock, a pharmaceuticals royalty management company, is a good buying opportunity at the present time. INVA stock trades near $12 currently and it is, in fact, down 17% from its...

4 months ago - Forbes

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

4 months ago - Zacks Investment Research

These are the biotech stocks with the best value, fastest growth, and most momentum for Q1 2021.

Other stocks mentioned: BDSI, BMRN, CPRX, NVAX, VRTX, VXRT, VYGR
4 months ago - Investopedia

Top Ranked Value Stocks to Buy for December 7th

Other stocks mentioned: CPLP, QFIN
5 months ago - Zacks Investment Research

To combat market volatility, it is of utmost importance to create a portfolio of low-beta stocks.

Other stocks mentioned: CWT, EGOV, OMI, SMP
5 months ago - Zacks Investment Research

Top Ranked Value Stocks to Buy for December 3rd

Other stocks mentioned: AMRK, QFIN
5 months ago - Zacks Investment Research

We have screened value stocks Amkor (AMKR), Innoviva (INVA), United States Cellular (USM), Old Republic (ORI) and Regal Beloit (RBC) based on EV-to-EBITDA ratio that offers a clearer picture of valuatio...

Other stocks mentioned: AMKR, ORI, RBC, USM
5 months ago - Zacks Investment Research

Top Ranked Value Stocks to Buy for December 1st

Other stocks mentioned: DAC, QFIN, XAN
5 months ago - Zacks Investment Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

5 months ago - Zacks Investment Research

Top Ranked Value Stocks to Buy for November 27th

Other stocks mentioned: DAC, ODP
5 months ago - Zacks Investment Research

Top Ranked Value Stocks to Buy for November 24th

Other stocks mentioned: DAC, ODP, UNFI
5 months ago - Zacks Investment Research

Top Ranked Value Stocks to Buy for November 19th

Other stocks mentioned: AMRK, NRIM, UNFI
5 months ago - Zacks Investment Research

Top Ranked Value Stocks to Buy for November 17th

Other stocks mentioned: GPP, UNFI, XAN
5 months ago - Zacks Investment Research

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("the Company") today reported financial results for the third quarter ended September 30, 2020. Gross royalty revenues of $92.2 millio...

6 months ago - Business Wire

Stocks continued yesterday's rally on more stimulus optimism and strong earnings, although Goldman Sachs expressed doubts about the stimulus package. For investors looking to make sense of the markets, ...

Other stocks mentioned: CL, JBHT, PGR, WEX
6 months ago - Forbes

Despite yesterday’s dip due to poor COVID vaccine and treatment news from Johnson and Johnson and Eli Lilly, the indices are up thus far in October. For investors looking to make sense of these unpreced...

Other stocks mentioned: EPAM, LAUR, PGR, PRSP
6 months ago - Forbes

These stocks are just temporarily inconvenienced large caps in the making.

Other stocks mentioned: ADUS, SUPN
7 months ago - The Motley Fool

These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: GMAB, MRSN, NVAX, REGN, TECH, VNDA, XBIT
7 months ago - Investopedia

With the approval for the asthma indication, Glaxo's (GSK) Trelegy becomes the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD.

Other stocks mentioned: GSK
7 months ago - Zacks Investment Research

The U.S. Food and Drug Administration (FDA) has approved Innoviva Inc.’s (NASDAQ: INVA) treatment of asthma and for patients with chronic obstructive pulmonary disease (COPD), the company announced, giv...

7 months ago - 24/7 Wall Street

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclid...

Other stocks mentioned: GSK
7 months ago - Business Wire

Innoviva (INVA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?

Other stocks mentioned: JAZZ, TBPH, TXAC, TXG
8 months ago - The Motley Fool

The Dow was lower this morning, on the day that they make major changes to their constituents after Apple's share split reduced tech influence in the index.

Other stocks mentioned: FBHS, LH, THO, WSM
8 months ago - Forbes

All major indices are in the green as the investors digested the speech by the Federal Reserve, taken as positive for equities. Tech stocks have also been driving the markets higher, propelling indices ...

Other stocks mentioned: D, GLT, VMC
8 months ago - Forbes

These two stocks are probably undervalued, but that won’t last forever.

Other stocks mentioned: ALXN
8 months ago - The Motley Fool

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc.

9 months ago - Business Wire

During Innoviva's (INVA) upcoming Q2 earnings call, investor focus will be on the royalties earned that comprise the company's top line.

9 months ago - Zacks Investment Research

Shareholders of Invesco Mortgage Capital Inc (NYSE:IVR) and Innoviva Inc (NASDAQ:INVA) have witnessed their stocks underperform the S&P 500 index over the past one-year, three-year and five-year periods.

Other stocks mentioned: IVR
10 months ago - GuruFocus

Is (INVA) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

Innoviva (INVA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

Innoviva (INVA) closed at $14.13 in the latest trading session, marking a -0.77% move from the prior day.

10 months ago - Zacks Investment Research

These are the biotech stocks with the best value, fastest growth, and most momentum for Q3 2020.

Other stocks mentioned: GMAB, IBB, NVAX, TRIL, VNDA, VRTX, XBIT
10 months ago - Investopedia

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

11 months ago - Zacks Investment Research

About INVA

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic ant... [Read more...]

Industry
Biotechnology
IPO Date
Oct 5, 2004
CEO
Pavel Raifeld
Employees
5
Stock Exchange
NASDAQ
Ticker Symbol
INVA
Full Company Profile

Financial Performance

In 2020, Innoviva, Inc.'s revenue was $336.79 million, an increase of 29.03% compared to the previous year's $261.02 million. Earnings were $224.40 million, an increase of 42.67%.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Innoviva, Inc. stock is "Strong Sell" and the 12-month stock price forecast is 10.00.

Price Target
$10.00
Analyst Consensus: Strong Sell